HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Cited by other online articles Google Scholar Articles by Kenny, A. M. Articles by Prestwood, K. M. Articles citing this Article PubMed PubMed Citation Articles by Kenny, A. M. Articles by Prestwood, K. M.

Effects of Transdermal Testosterone on Cognitive Function and Health Perception in Older Men With Low Bioavailable Testosterone Levels

^a Center on Aging, University of Connecticut Health Center, Farmington
^b Braceland Center for Mental Health and Aging, Institute of Living/Hartford Hospital, Connecticut

Anne M. Kenny, Center on Aging, MC-5215, University of Connecticut Health Center, Farmington, CT 06030-5215. Email: [email protected]

Background. Many men older than 50 years have bioavailable testosterone levels below the reference range for young adult men. The impact of the decreased androgen levels on cognition and health perception has received little attention.

Methods. Sixty-seven men (mean age 76 ± 4 years, range 65–87) with bioavailable testosterone levels below 128 ng/dl (lower limit for adult normal range) were randomized to receive transdermal testosterone (2–2.5 mg patches/d) or placebo patches for 1 year. All men received 500 mg supplemental calcium and 400 IU vitamin D. Outcome measures included sex hormones [testosterone, bioavailable testosterone, sex hormone binding globulin (SHBG), estradiol, and estrone], cognitive tests (Digit Symbol, Digit Span, Trailmaking A and B), health perception (Medical Outcome Survey Short-form 36 or SF-36), lower extremity muscle strength and power, and calcium intake.

Results. Twenty-three men (34%) withdrew from the study; 44 men completed the trial. Bioavailable testosterone levels increased from 93 ± 34 (SD) to 162 ± 100 ng/dl (p < .002) at 12 months in the testosterone group (n = 24) while no change occurred in the control group (n = 20). While there was no change in estradiol levels in either group, estrone levels increased in the testosterone group (28 ± 7 to 32 ± 9 pg/dl, p = .017). Scores on the Digit Symbol test improved in both the testosterone and placebo groups. Scores on Trailmaking B improved in men treated with testosterone (p < .005), although the changes were not statistically different from the changes seen in the placebo group. Twelve-month scores on Trailmaking B for the entire group were correlated with 12-month testosterone levels (p = .016). Scores for health perception measured by SF-36 did not change significantly, though scores of mental and general health declined in both groups during the 12-month intervention. Twelve-month bioavailable testosterone scores were directly correlated with scores for physical role (p = .022), vitality (p = .036), and the physical composite score (p = .010).

Conclusions. Transdermal testosterone treatment in men with low bioavailable testosterone levels does not impair and may improve cognitive function. Treatment did not improve health perception but this may have been due to the side effects of skin irritation suggested by similar reactions in both the testosterone and placebo groups.

This article has been cited by other articles: (Search Google Scholar for Other Citing Articles)

				P. H. Lu, D. A. Masterman, R. Mulnard, C. Cotman, B. Miller, K. Yaffe, E. Reback, V. Porter, R. Swerdloff, and J. L. Cummings Effects of Testosterone on Cognition and Mood in Male Patients With Mild Alzheimer Disease and Healthy Elderly Men Arch Neurol, February 1, 2006; 63(2): 177 - 185. [Abstract] [Full Text] [PDF]

				C. N. Lessov-Schlaggar, T. Reed, G. E. Swan, R. E. Krasnow, C. DeCarli, R. Marcus, L. Holloway, P. A. Wolf, and D. Carmelli Association of sex steroid hormones with brain morphology and cognition in healthy elderly men Neurology, November 22, 2005; 65(10): 1591 - 1596. [Abstract] [Full Text] [PDF]

				M. M. Cherrier, A. M. Matsumoto, J. K. Amory, S. Ahmed, W. Bremner, E. R. Peskind, M. A. Raskind, M. Johnson, and S. Craft The role of aromatization in testosterone supplementation: Effects on cognition in older men Neurology, January 25, 2005; 64(2): 290 - 296. [Abstract] [Full Text] [PDF]

				J. E. Morley Editorial. Mobility Performance: A High-Tech Test for Geriatricians J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2003; 58(8): M712 - 714. [Full Text] [PDF]

				J. E. Morley The Need for a Men's Health Initiative J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2003; 58(7): M614 - 617. [Full Text] [PDF]

				J. E. Morley and H. M. Perry III Androgens and Women at the Menopause and Beyond J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M409 - 416. [Full Text] [PDF]

				S. H. Tariq MD KNOWLEDGE ABOUT LOW TESTOSTERONE IN OLDER MEN J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M382 - 383. [Full Text] [PDF]

				W. A. Banks and J. E. Morley Memories Are Made of This: Recent Advances in Understanding Cognitive Impairments and Dementia J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M314 - 321. [Full Text] [PDF]

				J. E. Morley Editorial: Hot Topics in Geriatrics J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2003; 58(1): M30 - 36. [Full Text] [PDF]

				J. E. Morley Editorial: Citations, Impact Factor, and the Journal J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2002; 57(12): M765 - 769. [Full Text] [PDF]